Companies › NewAmsterdam Pharma
3 active drug programs in 26 registered trials: 12 Phase 4, 7 Phase 3, 7 Phase 2; Neurology, Cardiovascular, Metabolic and endocrine, Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| obicetrapib Cholesteryl ester transfer protein inhibitor | CETP | Phase 3 | Atherosclerotic Cardiovascular Disease; Lipidemia; Dyslipidemias; Antioxidant Absorption … | Nov 2026 |
| ezetimibe Niemann-Pick C1-like protein 1 inhibitor | NPC1L1 | Phase 3 | Lipidemia; Atherosclerotic Cardiovascular Disease With Dyslipidemia; Atherosclerotic Cardiovascular Disease (ASCVD); Type 1 Diabetes … | Nov 2027 |
| evolocumab Subtilisin/kexin type 9 inhibitor | PCSK9 | Phase 2 | Dyslipidemias; Type 1 Diabetes; Stroke, Ischemic; STEMI - ST Elevation Myocardial Infarction … | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05537948 | evolocumab | Phase 4 | Dyslipidemias | Metabolic and endocrine | Jan 2024 |
| NCT06784557 | ezetimibe | Phase 4 | Atherosclerotic Cardiovascular Disease With Dyslipidemia | Cardiovascular | Jul 2025 |
| NCT06081803 | evolocumab | Phase 3 | ST Elevation Myocardial Infarction | Cardiovascular | Dec 2025 |
| NCT05202509 | obicetrapib | Phase 3 | Atherosclerotic Cardiovascular Disease | Cardiovascular | Nov 2026 |
| NCT06496243 | obicetrapib | Phase 2 | Dyslipidemias | Cardiovascular | Nov 2026 |
| NCT06496243 | evolocumab | Phase 2 | Dyslipidemias | Cardiovascular | Nov 2026 |
| NCT06982508 | obicetrapib | Phase 2 | Antioxidant Absorption | Other | Dec 2026 |
| NCT07839741 | ezetimibe | Phase 4 | Atherosclerotic Cardiovascular Disease (ASCVD) | Cardiovascular | Jan 2027 |
| NCT05641753 | ezetimibe | Phase 4 | Type 1 Diabetes | Metabolic and endocrine | Jul 2027 |
| NCT05641753 | evolocumab | Phase 4 | Type 1 Diabetes | Metabolic and endocrine | Jul 2027 |
| NCT04499859 | ezetimibe | Phase 4 | Myocardial Infarction | Cardiovascular | Aug 2027 |
| NCT06305559 | obicetrapib | Phase 3 | Lipidemia | Cardiovascular | Nov 2027 |
| NCT06305559 | ezetimibe | Phase 3 | Lipidemia | Cardiovascular | Nov 2027 |
| NCT03753555 | evolocumab | Phase 4 | Stroke, Ischemic | Neurology | Nov 2027 |
| NCT04968509 | evolocumab | Phase 3 | Aortic Stenosis | Cardiovascular | Dec 2027 |
| NCT06437574 | ezetimibe | Phase 2 | Prostate Cancer | Oncology | Feb 2028 |
| NCT07219602 | obicetrapib | Phase 3 | Lipidemia | Metabolic and endocrine | Mar 2028 |
| NCT07219602 | obicetrapib | Phase 3 | Lipidemia | Metabolic and endocrine | Mar 2028 |
| NCT04951856 | evolocumab | Phase 4 | STEMI - ST Elevation Myocardial Infarction | Cardiovascular | May 2028 |
| NCT07794670 | obicetrapib | Phase 2 | Preclinical Alzheimer's Disease | Neurology | Sep 2028 |
| NCT06284564 | evolocumab | Phase 2 | Metastatic Renal Cell Carcinoma | Oncology | Oct 2028 |
| NCT07612774 | evolocumab | Phase 4 | Coronary | Cardiovascular | Oct 2028 |
| NCT06186037 | ezetimibe | Phase 4 | Coronary Artery Disease | Cardiovascular | Feb 2029 |
| NCT07307989 | ezetimibe | Phase 2 | Ischemic Stroke | Neurology | Jul 2029 |
| NCT06767774 | ezetimibe | Phase 4 | ASCVD | Metabolic and endocrine | Aug 2029 |
| NCT07611747 | ezetimibe | Phase 4 | Rheumatoid Arthritis (RA) | Immunology | Apr 2031 |
Cash and short-term investments of $628m on 2026-09-30; operating cash outflow about $147m a year; runway about 51 months at that burn, to Jan 2031; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Lexicon Pharmaceuticals Eidos Therapeutics, a BridgeBio company Amylyx Pharmaceuticals Brainfarma Industria Química e Farmacêutica S/A THPharm
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.